April 12, 2023

Willkie represented Clovis Oncology, Inc. in the sale of its oncology drug Rubraca (rucaparib) to pharma& Schweiz GmbH in a bankruptcy 363 sale.

Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, initiated a chapter 11 proceeding in December in order to sell its assets through a court-supervised process.

The Willkie corporate team was led by partners Thomas Mark and Erin Kinney. The bankruptcy team was led by partners Rachel Strickland and Andrew Mordkoff. 
Thomas Mark
Thomas Mark Partner Corporate & Financial Services
Erin Kinney
Erin C. Kinney Partner Corporate & Financial Services
Andrew Mordkoff
Andrew S. Mordkoff Partner Business Reorganization & Restructuring
Rachel C. Strickland Partner Business Reorganization & Restructuring